The Promise of Peptide Therapeutics
PTG-100 PTG-200 PTG-300
June 18, 2020Hepcidin Mimetic PTG-300 Receives U.S. FDA Orphan Drug Designation for the Treatment of Polycythemia Vera More

Welcome to Protagonist, a clinical-stage biopharmaceutical company poised to deliver life-changing therapies.

Clinical-stage new peptide entities addressing unmet medical needs

Learn More

Executive team with broad industry experience and success in drug development

Learn More

Collaborations with pharma giants and grassroots advocates

Learn More